All In Biotech

Drug Trial Radar · NCT06628206

Safety and Pharmacokinetics of LPX-TI641 in Rheumatoid Arthritis and Psoriatic Arthritis

Phase 1b Randomized, Double Blind, Placebo-controlled Study to Evaluate Safety, Tolerability and Pharmacokinetics of LPX-TI641 in Patients With Rheumatoid Arthritis and Psoriatic Arthritis

Last checked: Nov 20, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

48

Planned (sponsor's estimate)

Start

Dec 15, 2024

Primary completion

Nov 15, 2026

Study completion Feb 15, 2027

Sponsor

Lead sponsor
LAPIX Therapeutics Inc.Industry
Sponsor type
Industry
First posted
Oct 4, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to study the drug LPX-TI641 in patients with rheumatoid arthritis and psoriatic arthritis. We will compare the safety and tolerability of LPX-TI641 to placebo that contains no drug. We will also evaluate the plasma pharmacokinetics of LPX-TI641. LPX-TI641 (or placebo) will be administered orally for 28 days.

Conditions

  • Rheumatoid Arthritis (RA)
  • Psoriatic Arthritis (PsA)

Interventions

  • LPX-TI641Drug

    Oral administration QD for 28 consecutive days

  • PlaceboDrug

    Drug is LPX-TI641. Placebo an identical formulation without the LPX-TI641.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate the safety and tolerability after multiple oral doses of LPX-TI641 in participants with RA and PsA.Time frame: 56 days

Locations

6 sites in 2 countries. Site status is shown where the registry gives one.

  • Universal Medical Center

    Homestead, Florida

  • Regenerate Primary Medical Research

    South Miami, Florida

  • Red River Research Partners

    Fargo, North Dakota

  • Altoona Center for Clinical Research

    Altoona, Pennsylvania

  • Clinical Investigations of Texas

    Plano, Texas

  • Triumpharma Clinical Research Unit at AlEssra Hospital

    Amman, Jordan, Jordan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.